No abstract available.
Female ; Humans ; Osteoporosis* ; Uterine Prolapse*

BACKGROUND: The pathophysiology of non ulcer dyspepsia remains unknown. But Several related factors have been investigated and psychologic factor is one of the possible mechanism. Alexithymia was introduced to explain the psychopathology of psychosomatic disorder. Until now alexithymia has been variously shown to be associated with many psychosomatic disorder, psychiatric disorder, even medical patients. This study is designed to investigate whether non ulcer dyspepsia has more relationship with alexithymia than other illness. METHODS: To compare alexithymia tendency between non ulcer dyspepsia and general medical patients, we collected sample from January to September 1999. Each group of 72 patients were tested using Toronto Alexithymia Scale. RESULTS: A rate of 37.5% of alexithymia was found in the non ulcer dyspepsia group compared with significant lower rate of 19.4% in the general medical patients group. CONCLUSION: Non ulcer dyspepsia patients had more alexithymia compare to general medical patients. This finding shows the alexithymia could be part of the pathophysiology of non ulcer dyspepsia.
Affective Symptoms* ; Dyspepsia* ; Fibrinogen ; Humans ; Psychopathology ; Psychophysiologic Disorders ; Ulcer*

No abstract available.
Hair ; Humans ; Piedra ; Scalp ; Trichosporon

No abstract available.
Nevus

No abstract available.
Candida

No abstract available.
Onychomycosis

No abstract available.
Candida ; Onychomycosis

PURPOSE: This analysis was conducted to evaluate the cost-effectiveness of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patients in an outpatient setting compared with the traditional inpatient setting. METHODS: A cost-effective analysis was conducted from a societal perspective. The effects of treatment, which was measured as an adverse event rate, were abstracted from a published literature search and empirical data from one university hospital. The costs included both direct and indirect costs. Direct costs included hospitalizations, outpatient visits, and lab tests. Pharmaceutical costs were excluded in analysis because they were same for both options. Indirect costs included productivity loss of patients as well as care-givers. In order to determine the robustness of the results, sensitivity analysis on treatment protocol was conducted. RESULTS: Literature search showed no difference in adverse effect rates between inpatient treatment protocol and outpatient treatment protocol. Therefore, this analysis is a cost-minimization analysis. Cost-savings in the outpatient setting was 555,936 won for one treatment cycle. Our sensitivity analysis indicated that the outpatient chemotherapy still showed cost-savings, regardless of changes in treatment protocol. CONCLUSION: The outpatient gemcitabine-cisplatin chemotherapy for non small-cell lung cancer resulted in cost savings compared to inpatient chemotherapy. More importantly, outpatient chemotherapy could improve the utilization of health service resources in terms of available beds.
Antineoplastic Combined Chemotherapy Protocols/*economics/therapeutic use ; Carcinoma, Non-Small-Cell Lung/*drug therapy/*economics ; Cisplatin/*economics/therapeutic use ; Cost Allocation ; Cost-Benefit Analysis ; Deoxycytidine/*analogs & derivatives/economics/therapeutic use ; Humans ; Lung Neoplasms/*drug therapy/*economics ; Outpatients

PURPOSE: Orthostatic proteinuria accounts for the majority of cases of proteinuria that present in childhood or adolescent. This study was conducted to see the prevalence of Nutcracker syndrome (NCS) in children with orthostatic proteinuria using venography. METHODS: Study patients consisted of 23 children with orthostatic proteinuria. The diagnosis of NCS was made by high pressure gradients (> or =4 mmHg) between left renal vein (LRV) and inferior vena cava (IVC) in left renal venography and pressure tracing. RESULTS: Of 23 study patients, the venography showed 12 cases (52%) of typical NCS. Their mean age was 11.5 years (9-14 years). Female predominance (Male:Female=2:10) was noted. In NCS group (n=12), venous pressures of IVC and LRV were 6.50+/-3.34 and 13.21+/-3.53 mmHg, respectively. This pressure gradient between two veins was 6.71+/-2.54 mmHg, which is significantly higher than that of non-NCS group (n=11), 2.17+/-0.94 mmHg (p < 0.05). No positive correlation was observed between urinary protein during 24 hour and pressure gradient (r=0.152, p=0.636). CONCLUSION: NCS may be an important cause of orthostatic proteinuria in children. The prevalence of NCS shown in this study was very similar to that in a doppler sonographic observation published previously. A larger-scale study is necessary to confirm the prevalence.
Adolescent ; Child ; Female ; Humans ; Phlebography ; Prevalence ; Proteinuria ; Renal Veins ; Veins ; Vena Cava, Inferior ; Venous Pressure

Background: Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to the p19 subunit of interleukin-23. Risankizumab has demonstrated rapid and excellent therapeutic effects in several clinical trials. Although a growing number of studies have reported data on the real-world efficacy and safety of risankizumab for the treatment of psoriasis, no such study has been conducted in Korea. Objective: We evaluated the real-world efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis in Korean patients. Methods: This was a retrospective single-center study. A total of 33 patients treated with risankizumab, for at least 16 weeks, were enrolled. Based on electronic medical records, the clinical characteristics, psoriasis area and severity index (PASI) score, body surface area, and adverse events were investigated. Results: The mean PASI score was significantly reduced at 4 weeks of risankizumab treatment (3.27±2.15) and gradually reduced at week 16 (1.06±0.97) and week 52 (0.24±0.63) (p＜0.05). At week 16, all patients achieved a PASI 75 response, and 66.7% and 27.3% of patients achieved PASI 90 and PASI 100 responses, respectively. Obese patients (body mass index, BMI≥25 kg/m2 ) showed a lower PASI 90 response than non-obese patients (BMI＜25 kg/m2 ) at week 16. Older patients (age≥65 years) showed significantly higher PASI scores than younger patients (age＜65 years) at week 16. Mild to moderate adverse events were reported in four patients; however, no patient discontinued treatment. Conclusion Risankizumab was very effective in a real-world clinical practice with a favorable safety profile in Korean patients with moderate-to-severe psoriasis.